Prostate cancer and genetic haemochromatosis


The latest of my "30 articles in one month" series to raise money for prostate cancer research looks at a surprising overlap between my cancer and my wife's debilitating genetic condition: Celtic Curse.

 Celtic Curse is the genetic form of haemochromatosis

[Note: I pledged to produce these 30 articles in one month, even though I'm currently undergoing prostate cancer treatment, to meet a fundraising goal. Please consider donating here and sharing a link to this blog (CobbsBlog.com) on social media.]

What the heck is Celtic Curse?

When you look up Hereditary Hemochromatosis (HH)—often called "iron overload"—on standard public health portals like NHS England, the summary usually sounds manageable: a genetic condition where the body absorbs too much iron, leading to fatigue, joint pain, and if left untreated, risk of diabetes and liver disease or liver cancer.

While liver cancer is indeed the headline threat, standard public health pages often understate the broader picture. Mounting large-scale genetic research shows that untreated iron overload doesn’t just harm the liver; it creates a fertile environment for cancer cells to thrive throughout the body.

Understanding these risks—and knowing how easily they can be prevented—is a powerful reason to find out if you carry the genes for HH. 

But how does iron become fuel for cancer? 

Iron is vital for carrying oxygen in our blood, but in excess, it is volatile.When your body lacks the genetic "brakes" to regulate iron absorption—most commonly due to two copies of the C282Y gene mutation—excess iron spills out of normal storage proteins into your organs and bloodstream. This extra, unmanaged iron triggers two cellular disasters:Cellular Damage (Free Radicals): Free-floating iron reacts with oxygen to generate destructive molecules called free radicals. These molecules strip electrons from surrounding tissue, damaging cellular DNA and introducing mutations that can trigger cancer.Feeding Tumor Growth: Cancer cells have an aggressive appetite for iron. They use it to fuel rapid cell division and building new DNA. In short, excess tissue iron acts like high-octane fuel for early-stage tumor growth.The Numbers: Breaking Down the Real Cancer RisksTranslating complex genetic studies into clear, real-world numbers helps illustrate why early detection is critical.1. Liver Cancer: A 10-Fold Increase for MenThe most striking impact of untreated HH is on the liver, where the body stores the vast majority of excess iron.The Risk: Men with two copies of the primary HH gene mutation (C282Y homozygotes) are 10 times more likely to develop primary liver cancer compared to the general population.In Simple Terms: Roughly 1 in 14 men with untreated HH will develop liver cancer by age 75 (compared to less than 1 in 150 men without the mutation).The Unseen Risk: While liver cancer often follows cirrhosis (severe liver scarring), large studies show that 10% to 15% of HH patients who develop liver cancer have no cirrhosis at all. The excess iron directly damages DNA long before total organ failure occurs.2. Prostate Cancer: The Overlooked ConnectionWhile mainstream health sites rarely mention extrahepatic (non-liver) cancers, large population studies—such as the 450,000-person UK Biobank study—have uncovered significant links.The Risk: Men carrying two copies of the C282Y mutation show a 32% increased risk of developing prostate cancer.   In Simple Terms: About 1 in 7 men with high-risk HH genes are projected to develop prostate cancer by age 75, compared to about 1 in 10 in the broader population. Because iron accumulates in glandular tissues, the prostate appears particularly vulnerable to chronic oxidative stress.

..the specialist MDT now recommends radical treatment. We can offer either robot-assisted radical prostatectomy or hormone-ablation and radical radiotherapy...

There's that word radical again, and this time it is feeling very real. Either option is going to make a big difference to my life. If you are reaching this point,

The company's website has some useful educational materials including more extensive list of different types of radiotherapy.



Handling prostate cancer radiotherapy sessions: useful things to know


This article gets into the nitty gritty of one particular aspect of prostate cancer treatment: radiotherapy. It's 15 out of 30 articles I'm publishing in November to raise awareness and understanding of prostate cancer.

 Control panel for radiotherapy system to prostate cancer

[Note: I pledged to produce these articles, even though I'm currently undergoing prostate cancer treatment, to raise money for cancer research and support. I pledged to publish "30 for £300" and ask for donations to hit that goal. You can donate here — please consider doing so, and telling others about this blog (CobbsBlog.com).]

When you first get diagnosed with prostate cancer, you may not want to tell the world about your diagnosis. I can understand that. I didn't tell many people when I was first diagnosed (2021), partly because the initial prognosis was pretty good. I was fortunate that for more than four years I had "only a tiny amount of non-aggressive cancer" and was not on any treatment.

That changed last year when a jump in my PSA numbers led to an MRI that indicated serious growth of the cancer in my prostate, which in turn led to a biopsy that confirmed it. I opted for "radical" treatment and chose radio therapy and hormone ablation over surgery.

By late spring of this year, many of my friends knew what what I was going through.  That led my oldest childhood friend to call me with when he got a very similar diagnosis. He opted for radiotherapy just as I weas completing mine so I offered some pointers, based on my experience. what follows is an expanded version of those notes.

My prostate cancer radiotherapy notes

In July of 2026, I underwent 20 radiotherapy sessions, one per day, every day except weekends, starting on the first of the month, which was a Wednesday. For detail oriented readers, the exact form of the treatment was high-energy X-ray photons delivered by an Elekta Versa HD linear accelerator. The total prescribed radiation dose was 60 Gray (Gy), divided into 20 daily treatments, or fractions, of 3 Gy each. This is known as moderately hypofractionated radiotherapy. 

All the sessions were completed on the day of the appointment, something I mention because this not always the case, for reasons that will become clear. 

Mental prep: 

I needed a way to think of my treatment as part of my life, which is basically "retired 70-something man looking after medically disabled wife and 97-year-old mother." I decided to think of the radiotherapy as a month’s holiday, with nothing to do but basic care chores and a part-time job, five days a week. I also told myself this would be followed by a complete fortnight of doing as little as possible but recover. Thankfully, my carees wanted to help by reducing demands on my time and energy where possible. As best I could, I cleared my calendar of obligations. I figured, the fewer tasks I had to perform in addition to attending the sessions, the better.

Physical prep: Each day you head to the treatment centre for a radiotherapy session your bladder needs to be full. Your bowel needs to be empty. And you should not be passing gas. These requirements relate to the targeting of the X-ray beam that has been carefully calibrated to kill the cancer cells. At some point prior to treatment you will have a scan that enables the radiotherapy team to figure out exactly where within your body the beam needs to be directed. That will be performed when you have a full bladder, empty bowel, and no gas. Therefore, they want you to replicate that state as closely as possible for every session. 

Logistics: The cancer centre is a 25-35 minute drive from my house depending of time of day due to traffic. I planned to drive myself to and from each session. (In practice, I never felt too tired to do this but it became more challenging as the weeks rolled on.)

Procedure: I am incredibly lucky that my treatment provided by a state of the art facility (supported by not one, but two universities), delivered by very well trained staff, highly professional but also warm, caring, and kind (#Gratitude). On arrival you check in and take a seat, thankfully in a comfy waiting area with a coffee and snack bar run by volunteers.

A technician comes out of the treatment area and calls your name. They introduce themselves with first name if they have not seen you before. They take you back to a private cubicle and scan your bladder: a quick drop of the trousers and underwear, a glob of gel on the tum, then a few probing swipes with an ultrasound wand. If the volume of fluid in your bladder is within the range established by your targeting scan you are led to a chair outside the treatment theatre.

After you walk into theatre you take off your shoes, climb onto the treatment bench, and again drop your trousers and underwear. Staff quickly place a piece of paper over your privates and then raise the bed to the right height for the beam targetting. Staff will already have the headrest, knee support, and foot stirrups configured exactly for your profile, aided by the system display like the one in the photo at the top of the article (taken by me, with permission). 

(FYI, this particular system contains a detailed 3D scan of your pelvic area, mapped by a separate machine about 30 days before treatment starts, in my case a Canon Aquilion Exceed LB CT.)

When you are resting as comfortably as you can, the technicians move the massive "ring of radio beams" from out from the wall so it is surrounding your pelvis. Then they exit the room and the ring rotates twice around your body while you lie as still as possible. In as little as five minutes the techs return and help you off the table. One more session accomplished!

Impacts: I never felt any pain during the sessions. But after the first three or four I found that I was increasingly tired in the afternoon and evening. Fortunately, on most days I had the option to nap and snooze in the latter part of the day to compensate.

I did notice changes to my bladder and bowel, likely caused by the radiation plus the demands of pre-session prep, a topic I will cover in a moment. The urge to pass water got more frequent and stronger, but sometimes less water came out than expected. One effect of this was increased sleep disruption. Another was the post-session water management.

Water management: the instructions for all sessions is that you arrive feeling “comfortably full” which is either ironic or funny or both. Why? Because most blokes who are getting this treatment have spent years trying to empty their bladders because they don't feel comfortable when they're full. It took me about half a dozen sessions to master this. I had several "go and pee this amount" moments before sessions could go ahead, and some "go drink some water and we'll try again" times as well. I also had one "go fart" days, but thankfully all 20 sessions were done on the set day.

Invariably, I would get off the treatment table with a strong need to pass water immediately. I had the nearest bathrooms memorized. However, I often found I needed a second pee about 10-15 minutes later. And a third pee 15-20 minutes after that. I coped by taking care of P1 in the closest loo to the treatment room, then hanging around the hospital coffee shop for P2. For P3, I made a note of loo facilities I could use on the drive home if needed. (I was given an “URGENT card” but never had to use it.)

The instructions I received to achieve “comfortably full” status prior to session included drinking 300 ml of water one hour before treatment time. I found this did not always work. For example, you need to be generally well-hydrated for this to work, otherwise the body uses the water to hydrate rather than fill bladder.

Several fellow patients I spoke to reported hot weather and activity-related dehydration on the day prior to a session could make ‘filling up’ slower. I then noticed a lot of blokes in the waiting room carried water bottles, a practice I adopted.

During my targeting session I was told to lose about 50 ml of water, no more or less, which was tricky, so I did practice some go-and-stop “precision peeing” before the treatments began.

Another handy skill is passing wind without passing water. I found this out because my second session was delayed by the presence of gas that was distending in my bowel. The trick is to fart standing up, not go sit on the loo where you might be tempted to pee. 

Micro-enemas

Bowel management with micro enemas: I can honestly say that the daily radiotherapy regimen taught me a lot about bowel management. The advice I received was to move my bowels about 90 minutes before the appointment and then use a micro enema to ensure the bowels were empty. 

I was very helpfully provided with a box of these before my targeting scan and advised to practice with them, which I did. They proved effect and not quite as uncomfortable as I feared. None of my sessions had to be postponed because of bowel contents. However, there were some days when I went in for treatment not 100% sure my bowels were empty.

That's where the digital imaging comes in: remember I said the "ring of radio beams goes round you twice? The first time is a camera pass, used to check your internals, including bowel and bladder status. For example, if there is gas distending your bowel, that needs to be passed. Likewise, anything other than a small amount of fecal matter. These things can block the full effect of the cancer-killing beams. The technicians will make final adjustments based in this imaging data, then start the actual beam delivery, which can take as little as 75 seconds.

Wider effects: I found the effect of radiotherapy on my stamina was cumulative. By session 13 I was definitely feeling less able to take on physical tasks. The last few days of treatment were a struggle, not so much going and getting the treatment but feeling knackered the rest of the day. 

Unfortunately, this cumulative effect continues for several days after the therapy. I tried to do as little as possible in the fortnight following the treatment. I have since learned that the effect of the radiation on the cancer cells also lasts beyond the sessions, adding to the feeling of being knackered after a few hours of activity. 

By the end of the radiotherapy I was tired, my butt was sore, and I was feeling the urge to pee too often for my liking. Fortunately, things improved over the next few weeks. However, I continue to experience the effects of the ongoing hormone therapy (daily tablets of Relugolix that cause fatigue, hot flushes, waking in the night, weight gain). 

Is it worth it?

Opting for non-surgical treatment of your prostate cancer can involve months of taking hormone tablets that have unpleasant side effects, then a targeting scan, followed by four weeks of radiotherapy sessions, them more months on the tablets. During all of this there is no way of knowing if the treatment has been successful (a factor discussed in this article). 

After cheerfully bidding the radiotherapy team farewell as you exit your final session nothing happens, not for a while. You will probably get notified of an appointment with the oncologist in six, eight, or even 12 weeks after the radiotherapy has ended. They will want a PSA test (mine was 0.5). That is considered promising: however, it's not until you come off the hormone tablets that the lasting effect of the radiotherapy can be tested. I take my last tablet on March 31st. I'm due to see the oncologist with an other PSA test result on April 15. My guess is that a score below 0.5 will be a win.

Hopefully this account is helpful for other folks facing the same treatment. If you have questions you can send them to cobbs @ fastmail.com and I will try to answer them.

Bonus wardrobe advice: Luckily, my radiotherapy was done in July and the weather was warm. That allowed me to attend every session in a pair of Columbia brand fishing shorts that have their own "package handler" or inner mesh lining (see photo, mine are black, not blue). AFAIK, Columbia no longer makes the Omnishade PFG shorts but you can find them on eBay - respectable enough to wear in public, and very easy to pull down and pull up (you know, for bladder scanning and giving the photon beam a clear shot).

p.s. Go for the black ones - they are less likely to show dribbles.


This is the 15th of the 30 posts I hope to publish in Movember, 2026
Please consider donating now, it will encourage me to complete the challenge.
Thank you!

US prostate cancer news: screening guidelines get major update


The latest of my "30 articles in one month" series to raise money for prostate cancer research covers news of updated guidelines for prostate cancer screening in the US.

  American Cancer Society announces new prostate cancer screening guidelines

 [Note: I pledged to produce 30 articles in one month, even though I'm currently undergoing prostate cancer treatment, to achieve a fundraising goal. Please consider donating here and sharing a link to this blog (CobbsBlog.com) on social media.]

As a public health issue, prostate cancer (PCa), has grown rapidly this century and is now comparable in scale to breast cancer (BCa). By some key numerical measures PCa has now overtaken BCa, for example in terms of UK deaths, recent UK diagnoses, and projected US new cases. The American Cancer Society has projected 333,830 new prostate cancer cases in 2026. Screening men for early signs of prostate cancer can reduce the death toll and the impact of treatment.

Good news! Major improvements in US prostate cancer screening guidelines

I'm genuinely excited that the American Cancer Society chose this month, November, 2026 to announce major changes to its prostate cancer screening guidelines, intended to improve detection and treatment of a disease that is projected to result in 33,000 deaths in the US this year. 

There is an excellent article about the changes in The Conversation, which interviewed Dr. Andrew Wolf, a physician at the University of Virginia who was one of the lead authors of the new guidelines. He walks readers through the changes and why they were made. 

A fundamental change is a call for proactive screening for prostate cancer. Instead of just recommending that people talk with their healthcare provider to decide whether or not screening is right for them, the new recommendation is urging doctors to act, based on factors like age and a person’s risk of developing prostate cancer. For example, for people at average risk of developing prostate cancer:

we recommend they be screened with the prostate-specific antigen, or PSA, blood test every two years from age 50 through 69.

(If that level of screening were to be adopted universally, in American and beyond, many prostate cancer deaths would be avoided and millions of men would stand a better chance of avoiding the suffering caused by late intervention and treatment.)

More specifically, the new recommendation for people at higher risk, including Black men and men with a strong family history of prostate cancer, is that they should be screened annually from age 45 to 69. 

A strong family history is defined as having a family member who was diagnosed with prostate cancer before age 65, or multiple family members diagnosed at any age. 

Furthermore, "people with a single family member diagnosed at age 65 or older should be screened every two years from age 45 years to age 69 years."

The article goes on to explain why the changes were made and what the current views are on the risks of prostate cancer. The full 36-page guidelines document is available here. I strongly recommend reading the account in The Conversation, 

In my article about PSA testing I mentioned that I would address arguments about prostate cancer screening. I'm not going to do that here. However, I do need to point out that there are considerable differences between countries on this topic, due in part to the way those countries are structured. 

For example, if you have a national universal healthcare system (e.g. England), then screening guidelines for health-related issues can become requirements that must be funded. However, if you don't have a national universal healthcare system (e.g. USA), then medical guidelines are more aspirational, as in "this is what we hope will happen" versus "here's what has to happen by law."

I explained the way these differences manifest themselves in the the implementation of cancer screening guidelines in this article.

P.S. I love the fact that the image at the top of the article, a screenshot of the American Cancer Society page announcing the changes to prostate cancer screening guidelines, features happy women. It reminds me of the conversation I overheard on day at the cancer treatment centre where I got my radiotherapy. Two women were talking, the receptionist and a woman who had brough her husband in for treatment, and they were strongly agreeing with each other that "every man should be screened, just like everyone with breasts is screened."


Prostate cancer Q&A: How will I know if the radiotherapy worked?


Some of the articles in the 30-article series that I am publishing to raise money for prostate cancer research are answers to readers' questions. Today's question is about assessing the results of radiotherapy treatment.

Photo of radiotherapy machine in use for prostate cancer treatment Memorial Sloan Kettering Cancer Center
  Radiotherapy machine being used for prostate cancer treatment

[Note: I pledged to produce these articles while undergoing prostate cancer treatment, to raise money for the Movember charity which funds a lot of prostate cancer research and support. Please consider donating here and sharing a link to this blog (CobbsBlog.com) on social media.]

So, here is the exact wording of the reader's question: 

"How will they know how well the IMRT worked?" 

IMRT is a form of radiotherapy that the reader is considering and he wants to know how doctors determine the extent to which it succeeds in killing cancer cells.

For readers who don't recognize IMRT, it stands for Intensity-Modulated Radiation Therapy (IMRT), a type of external-beam radiotherapy used to treat localised prostate cancer, i.e. cancer that is in or very close to the prostate gland. 

As it happens, this is the type of radiotherapy that I had. (It was on a machine a bit like the one in picture at the top of the article, but there were no modesty blankets involved, staff just had you lie flat on the deck and drop your trousers and underwear.) 

My IMRT was delivered using a technique called Volumetric Modulated Arc Therapy (VMAT). Rather than delivering radiation from a series of fixed positions, VMAT delivers a continuously modulated beam while the machine rotates around the patient.

The question of how to determine if this treatment has been effective in a logical one, but the answer is somewhat frustrating: it's hard to know for sure, at least not straight away. In fact, it can take years, which is not exactly encouraging, but there are reasons for this.

Unlike surgery, where the prostate is removed and examined, radiotherapy leaves the prostate in place and there is no simple test that tells you if all the cancer cells have been destroyed.

What doctors can do is monitor PSA levels using blood tests (described here in a previous article). Successful radiotherapy should cause PSA levels to fall considerably, although they won't necessarily reach zero because healthy prostate cells are still producing some PSA.

This decline can take quite a while. It may be 18 months to three years before PSA reaches its lowest level, known as the nadir. And even after that a small temporary increase in PSA may occur, but that doesn't necessarily mean the cancer is returning. (There's a recognised phenomenon called PSA bounce, where the level rises briefly before falling again.)

For patients like me, who received radiotherapy combined with androgen deprivation therapy (ADT), there's an additional complication. ADT suppresses testosterone, which also reduces PSA production. So a low PSA reading while taking ADT is encouraging, but it doesn't tell us how much of the improvement is due to radiotherapy and how much is due to hormone suppression. 

In March of this year, before any treatment, my PSA was 7.50. After 50 days of ADT it was 0.47. In July I had the IMRT. About 75 days after the IMRT was completed my PSA was 0.45. The ADT doesn't end until the end of March and the drug won't clear my system right away. Realistically, it could be MAY until I get a PSA reading that is not influenced by testosterone suppression.

When ADT ends and testosterone recovers, PSA may rise somewhat, but that does not mean the cancer has returned. As I have said before, it is the trend of PSA numbers that matters. One widely accepted definition of recurrence after radiotherapy is a PSA increase of 2 above its lowest recorded level, but a  persistent upward trend may prompt investigation even before that threshold is reached.

(In the UK, the NHS recommends PSA checks at least every six months for the first two years following radical treatment, and annually thereafter. Routine scans or biopsies are generally unnecessary unless PSA results or symptoms suggest a problem.)

So the short answer is that the success of IMRT is judged over time, through regular PSA testing. A sustained low PSA is very good news and the longer it stays low, the more confident one can be that the treatment has done its job.

Types of radiotherapy

To put IMRT in context, here is a table based on info from Prostate Cancer UK, which has an excellent page on radiotherapy that is worth reading.

Technique

How it works

Current role

3D Conformal Radiotherapy (3D-CRT)

Uses CT-based planning to shape radiation beams to the prostate.

Older technique, largely superseded by IMRT for prostate cancer.

Intensity-Modulated Radiotherapy (IMRT)

Adjusts the intensity of radiation across individual beams, reducing exposure to surrounding tissues.

Standard UK treatment.

Volumetric Modulated Arc Therapy (VMAT)

A form of IMRT in which the machine rotates around the patient, continuously adjusting the beam.

Widely used in NHS radiotherapy centres.

Stereotactic Body Radiotherapy (SBRT/SABR)

Delivers very precise, higher doses of radiation in fewer sessions, often five.

Increasingly used for selected prostate cancers. 

Proton Beam Therapy (PBT)

Uses protons rather than X-ray photons, potentially reducing radiation beyond the target.

Not routine NHS treatment for localised prostate cancer; clinical benefit over modern IMRT remains uncertain.


One of the leading makers of radiotherapy equipment is Elekta. The company's website has some useful educational materials including more extensive list of different types of radiotherapy.



Prostate cancer: where to get help, advice, and support


This article is one of 30 that I am publishing to raise money for prostate cancer research. It lists major sources of help and support across multiple countries..

Image of eight men shown as icons, with one a different colour to show 1 in 8 men get prostate cancer
Prostate cancer prevalence is 1 in 8, even higher among black men
(from Prostate Cancer UK) 

[Note: I pledged to produce these articles, even though I'm currently undergoing prostate cancer treatment, for a fundraising pledge to which you can donate here. Please consider doing so and sharing a link to this blog (CobbsBlog.com) on social media.]

Getting a prostate cancer diagnosis can leave you with a lot of questions. Even after treatment has started, questions will likely keep coming up. Some concern the disease itself, others the side effects of treatment, and still others the impact on relationships, work, and everyday life (whether you are working or retired or retired but caring for a loved one). 

Fortunately, there are organisations that can help. Some have specialist nurses available to answer questions, while others can put you in touch with people who have already been through similar experiences. Most offer their services free of charge, and many also provide support for partners and families. 

For me, online support forums have been helpful. I starting hanging out at Prostate Cancer UK even before I had the results of my first MRI. Everyone was understanding and supportive. I suggest finding a forum sooner rather than later. Problems involving sexual function, fatigue, sleep, mood, continence, or relationships are legitimate reasons to engage with fellow patients, in addition to contacting a support organisation's clinical team about treatment or rehabilitation options.

I also found the nurse specialists at my cancer treatment centre to be very helpful. They pointed me to a local support group and I have found it helpful to attend some of their meetings.

United Kingdom

Prostate Cancer UK: Support services. Specialist nurses, confidential advice, online communities, and one-to-one peer support. Free helpline: 0800 074 8383. 

Tackle Prostate Cancer: tackleprostate.org. The National Federation of Prostate Cancer Support Groups. Particularly useful for finding local groups, meeting fellow patients and getting help with treatment decisions. 

Macmillan Cancer Support: Website and support line. Advice on cancer treatment, emotional wellbeing, finances, benefits and practical problems. Free helpline: 0808 808 00 00. 

Prostate Cancer Research: The Infopool. Patient-friendly information on diagnosis, treatment choices, clinical trials, managing side effects and life after treatment. Includes personal experiences from patients and partners. 

United States

ZERO Prostate Cancer: Help and support. National prostate cancer support organisation offering patient navigation, local and online support groups, one-to-one mentoring, and financial assistance guidance. ZERO360 helpline: 1-844-937-6360. 

Prostate Cancer Foundation (PCF): Support includes extensive patient education covering diagnosis, treatments, side effects, sexual health, clinical trials and survivorship. Free patient guides and webinars. 

Prostate Cancer Research Institute (PCRI): Evidence-based information, videos, educational conferences and a free patient helpline. Particularly useful when understanding treatment options and navigating complex decisions. 

CancerCare: Prostate cancer support. Free professional counselling, support groups, practical advice and financial assistance resources for patients and their families. 

Canada

Prostate Cancer Foundation Canada: National network offering prostate cancer support groups, peer support, information and education. Patient support: 604-834-7757. Toll-free general contact: 1-877-840-9173. 

Canadian Cancer Society: Cancer Information Helpline. Confidential information about cancer treatment, side effects, emotional wellbeing, clinical trials and community services. Available in English and French, with interpretation for other languages. Toll-free: 1-888-939-3333. 

CancerConnection.ca: Online support community. A free, moderated online community operated by the Canadian Cancer Society, connecting patients, survivors, partners and caregivers to share experiences and advice. 

Australia

Prostate Cancer Foundation of Australia (PCFA): National prostate cancer support services including specialist nurses, peer mentoring through MatesCONNECT, online communities and local support groups. Free helpline: 1800 22 00 99. 

PCFA Prostate Cancer Counselling Service: Counselling service. Specialised counselling for the emotional and psychological effects of prostate cancer, including sexual concerns, relationships, anxiety and depression. Offers up to five consultations without charge. Access via 1800 22 00 99. 

Cancer Council Australia: National cancer information, emotional and practical support, and referrals to local services. Telephone: 13 11 20. 

New Zealand

Prostate Cancer Foundation of New Zealand (PCFNZ): Support services. Specialist information, counselling, online forums, local support groups, exercise programmes and assistance for patients and their families. Information service: 0800 66 0800. 

Cancer Society of New Zealand: Cancer information nurses, counselling and practical support, including transport to treatment and assistance for families and carers. Free helpline: 0800 CANCER (0800 226 237). 

PCFNZ Local Support Groups: Nationwide directory connecting patients and families with local groups and experienced volunteers. Includes groups specifically for partners and informal one-to-one support. 

Cancer Screening: Prostate and breast cancer compared, US and UK


For the tenth article in the 30-article series I'm publishing to raise money for prostate cancer research I look at the differences between prostate and breast cancer screening in the US and UK.

 Caption: PSA blood test for prostate cancer screening
 & mammogram for breast cancer screening

[Note: I pledged to produce these articles, even though I'm currently undergoing prostate cancer treatment, for a fundraising pledge to which you can donate here. Please consider doing so and sharing a link to this blog (CobbsBlog.com) on social media.]

As someone who has lived for decades in both the UK and America I have noticed significant differences in how the two countries check for breast and prostate cancers. The US relies heavily on automatic, aggressive screening starting at younger ages. The UK takes a more conservative approach based on population health data, waiting longer to start routine tests and avoiding them entirely if the risks outweigh the benefits. 
The primary difference lies in how their medical systems work: the US often urges screening of individual patients earlier, but lacks a system to enforce this; the UK uses structured national programmes that only invite specific age groups, but has established mechanisms to make sure the screening happens. 
I thought it would be interesting to look at how prostate and breast cancer screening compare these days, given that the incidence of prostate cancer (PCa), has increased significantly this century and is now comparable in scale to breast cancer (BCa). By some key numerical measures PCa has now overtaken BCa, for example in terms of UK deaths, recent UK diagnoses, and projected US new cases.

Breast cancer screening

Both countries use mammograms (breast X-rays) to look for early signs of cancer, but who gets invited and how often varies greatly:

Screening Factors United States (US)United Kingdom (UK)
Starting Age Age 40 (Recommended by the US Preventive Services Task Force)Age 50 to 53 (Automatically invited by the NHS Breast Screening Programme)
How OftenEvery 1 to 2 years (Depending on the specific medical guideline)Every 3 years
Stopping AgeOften up to age 74, or as long as life expectancy is 10+ yearsAutomatically stops at age 71 (Though you can still request free tests)
US guidelines focus on catching cancer as early as possible in individuals. UK experts believe that routine screening for women under 50 causes more harm than good, such as unnecessary anxiety and extra testing for harmless lumps.

Prostate cancer screening

Neither the UK nor the US has a standard, automatic national screening programme for the general public. Both use the PSA blood test (Prostate-Specific Antigen), but their strategies differ significantly:
  • United States (Shared Decision Making): The US Preventive Services Task Force recommends that men aged 55 to 69 talk to their doctors to make a personal choice about screening. Doctors routinely offer this conversation during yearly checkups.
  • United Kingdom (Informed Choice / Targeted): The UK National Screening Committee explicitly advises against general population screening. Under the NHS Prostate Cancer Risk Management Programme, GPs do not proactively bring up the test. However, any man over 50 can request a free PSA test if they ask for it. The NHS only proactively invites men aged 45 to 61 if they have a known high-risk genetic mutation like BRCA2.
A major challenge for prostate cancer screening is that the PSA blood test is not a reliable as a direct indicator of cancer. It can show high levels due to a naturally enlarged prostate or an infection. The UK strictly limits its use because diagnosing slow-growing prostate cancers can lead to invasive treatments (like surgery) that cause side effects like impotence or incontinence, even if the cancer was never going to threaten the man's life. 

How is screening policy implemented?

A major reason for the differences in approach to cancer screening in different countires is the different ways in which those countries are structured. For example, if you have a national universal healthcare system (e.g. England), then screening guidelines for health-related issues can become requirements that must be funded. However, if you don't have a national universal healthcare system (e.g. USA), then medical guidelines are more aspirational, as in "this is what we hope will happen" versus "here's what has to happen by law." Here's a brief comparison:
  • UK: Screening policy is coordinated nationally by the UK National Screening Committee (UK NSC), which evaluates evidence on population benefit versus harm. Clinical pathways and referral standards are subsequently shaped by the National Institute for Health and Care Excellence (NICE) and delivered uniformly through the National Health Service (NHS).
  • US: There is no single, centralized national screening program. Instead, guidelines are issued by a mosaic of federal task forces (such as the US Preventive Services Task Force, or USPSTF), government research bodies (like the National Institutes of Health / National Cancer Institute, NIH/NCI), and professional organizations (such as the American Cancer Society, ACS, and specialty medical colleges). Screening frequently happens opportunistically during routine clinical encounters, heavily mediated by health insurance coverage.
When it comes to screening for PCa, what the UK and USA have in common is strong debate about the correct approach. Recent decisions in the UK appear to restrict PCa screening, and there has been strong pushback. Meanwhile in America, the American Cancer Society is expected to release revised PCa screening guidelines this month.